The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1432-0851
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC ; day:23 ; month:1 ; year:2022 ; pages:1-18
Cancer immunology immunotherapy ; (23.1.2022), 1-18

Urheber
Guti, Eliza
Regdon, Zsolt
Sturniolo, Isotta
Kiss, Alexandra
Kovács, Katalin
Demény, Máté
Szöőr, Árpád
Vereb, György
Szöllősi, János
Hegedűs, Csaba
Polgár, Zsuzsanna
Virág, László
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s00262-022-03146-z
URN
urn:nbn:de:101:1-2022050511035468557663
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:27 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Guti, Eliza
  • Regdon, Zsolt
  • Sturniolo, Isotta
  • Kiss, Alexandra
  • Kovács, Katalin
  • Demény, Máté
  • Szöőr, Árpád
  • Vereb, György
  • Szöllősi, János
  • Hegedűs, Csaba
  • Polgár, Zsuzsanna
  • Virág, László
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice

Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R

Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

MZ1 co-operates with trastuzumab in HER2 positive breast cancer

MZ1 co-operates with trastuzumab in HER2 positive breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer

Biased activation of the receptor tyrosine kinase HER2

Biased activation of the receptor tyrosine kinase HER2

Verbundene Objekte